Skip To Main Content

Science at Sanofi

Sort by

Filter

Reset
  • Therapeutical Areas
Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States

Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States

เทียบความต่าง ก่อน-หลัง ฉีดวัคซีน MenACWY จากอุบัติการณ์ของโรคไข้กาฬหลังแอ่นในสหรัฐฯ

LMWH : Antithrombotic choice with key features to diverse needs of your patient with active cancer

LMWH : Antithrombotic choice with key features to diverse needs of your patient with active cancer

aP vs wP pertussis vaccines

aP vs wP pertussis vaccines

The impact of influenza vaccination on cardiovascular disease

The impact of influenza vaccination on cardiovascular disease

ฉีดวัคซีนไข้หวัดใหญ่! ช่วยผู้ป่วยโรคหัวใจได้ดี

Economic Assessment of Incorporating the Hexavalent Vaccine as Part of the National Immunization Program of Peru

Economic Assessment of Incorporating the Hexavalent Vaccine as Part of the National Immunization Program of Peru

เปรูใช้วัคซีนรวม 6 โรค ในการสร้างภูมิคุ้มกันในเด็กอายุต่ำกว่า 1 ปี

High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 years: Can We Do Better? A Systematic Literature Review

High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 years: Can We Do Better? A Systematic Literature Review

ยิ่งสูงอายุ... ยิ่งเสี่ยง Admit จากโรคไข้หวัดใหญ่

A Pragmatic Randomized Feasibility Trial of Influenza Vaccines

A Pragmatic Randomized Feasibility Trial of Influenza Vaccines

วิจัยเผย! ฉีดวัคซีนไข้หวัดใหญ่ ขนาด High Dose ช่วยลดอันตรายได้จริง

Switching from wP to aP pertussis vaccine

Switching from wP to aP pertussis vaccine

Extended Venous thromboembolism treatment in patients with active cancer

Extended Venous thromboembolism treatment in patients with active cancer

Physician’s recommendation is a key for patients adherence to VTE treatment.

Physician’s recommendation is a key for patients adherence to VTE treatment.

De-escalation strategies in anti-platelet therapy: Understanding when to switch from a potent agent

De-escalation strategies in anti-platelet therapy: Understanding when to switch from a potent agent

De-escalation reduces bleeding risks in ACS. There are different strategies that can be described as de-escalation including guided and unguided. What is the current evidence regarding the different de-escalation strategies? And which patients are candidates for de-escalation strategies? VDO from expert (Prof.Sibbing)

Are new-generation basal insulins truly better insulins?

Are new-generation basal insulins truly better insulins?

Let's hear from the expert. Dr.Perkin, University of Toronto reviews the 2nd generation basal insulin and translates its advanced profile into clinically meaningful practice.